inhibits Bcr - Abl kinase leading to apoptosis of imatinib - resistant cells
نویسندگان
چکیده
1. Abstract 2. Introduction 3. Materials and Methods 3.1. Plant material, extraction and purification 3.2. Reagents 3.3. Cell lines 3.4. Clinical Samples 3.4. Cytotoxicity assay/proliferation assay 3.5. Cell cycle analysis apoptosis assay 3.6. In-vitro kinase assay 3.7. Data analysis 4. Results 4.1. Discovery and preparation of NPB001-05 4.2. Effect of NPB001-05 on growth of Bcr-Abl positive and negative cells, primary cultures and normal human peripheral blood mononuclear cells (PBMCs) 4.3. NPB001-05 inhibits proliferation of leukemic cell lines independent of Bcr-Abl mutational status 4.4. NPB001-05 inhibits autophosphorylation of wt and resistant Bcr-Abl 4.5. Effect of NPB001-05 on CML clinical samples 4.6. NPB001-05 blocks cell cycle progressing and induces apoptosis of Bcr-Abl positive cells 4.7. In-vitro profiling of NPB001-05 on different kinases
منابع مشابه
Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation
Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. T315I Bcr-Abl is the most notorious point mutation to elicit acquired resistance to imatinib (IM), leading to poor prognosis. Therefore, it is urgent to search for additional approaches and targeting strategies to overcome IM resistance. We recently reported that platinum pyrithione (PtPT) potently inhi...
متن کاملNPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.
The deregulated activity of the Bcr-Abl tyrosine kinase provides a rational basis for the development therapeutics in all phases of Chronic Myelogenous Leukemia (CML). Although a well studied imatinib therapy has clinical success against CML, resistance to imatinib due to mutations in the kinase domain, especially T315I poses a major problem for the ultimate success of CML therapy by this agent...
متن کاملSorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, relapse with emerging imatinib resistance mutations in the BCR/ABL kinase domain poses a significant problem. Here, we show that the multikinase inhibitor sorafenib inhibits proliferation and induces ap...
متن کاملAnti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors (TKI). Therefore it is urgent to search for new measures to overcome TKI-resistance. Auranofin (AF), clinically used to treat rheumatic arthri...
متن کاملBcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Although chronic myelogenous leukemia (CML) is effectively controlled by Bcr-Abl kinase inhibitors, resistance to inhibitors, progressive disease, and incomplete eradication of Bcr-Abl-expressing cells are concerns for the long-term control and suppression of this disease. We describe a novel approach to targeting key proteins in CML cells with a ubiquitin-cycle inhibitor, WP1130. Bcr-Abl is ra...
متن کامل